Aeterna prostate cancer drug shows promise
14th Nov 2006, 06:12 GMT
Aeterna Zentaris has presented detailed positive phase II results in hormone-dependent, inoperable prostate cancer for its compound ozarelix.
Aeterna prostate cancer drug shows promise related news:
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- A transmission electron micrograph shows a prostate cancer cell. ... — Top Stories Photos - Reuters on Yahoo! News Photos
- Anti-cancer drug shows early promise in pulmonary hypertension — EurekAlert! - Breaking News
- Prostate-specific symptoms of prostate cancer in a German general population — Prostate Cancer and Prostatic Diseases
- Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up — Prostate Cancer and Prostatic Diseases
- 'Muscle' Protein Drives Prostate Cancer — Health News from Medical News Today
- Scientists Design A PSA-Activated Protoxin That Kills Prostate Cancer — Health News from Medical News Today
- Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way — Health News from Medical News Today
- Drug That Interrupts A Key Stage Of Cell Division Shows Promise For Advanced Solid Tumors — Health News from Medical News Today
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Isis says new drug effective against cholesterol
- ZymoGenetics, Serono present positive results for atacicept